Through the recent increased attention to TNFR2, we found that whereas TNFR1 effectively promotes cancer cell death by activating NF-κB signaling, the activation of TNFR2 on tumor cells and immunosuppressive cells might be detrimental to anticancer therapy. The gene discussed is TNFRSF1B; the disease is neoplasm.